Crbn-I391V
Nomenclature
C57BL/6Smoc-Crbnem1(I391V)Smoc
Cat. NO.
NM-KI-200331
Strain State
Repository Live
Gene Summary
Gene Symbol
Crbn
Model Description
Validation Data
Fig1. CRBN modulators induced IL-2 secretion and Aiolos degradation in Crbn-I391V point mutation mice.
（A）Analysis of IL-2 production in naive CD4+ T cells by ELISA. After Lenalidomide 5000nM or Pomalidomide 5000nM treatment, CRBN modulators induced IL-2 secretion in naive CD4+ T cells.（B）Analysis of Aiolos expression in the spleen by FACS. After Lenalidomide 10uM or Pomalidomide 5000nM treatment, the AIOLOS expression decreased obviously in CD19+ B cells and CD3+ T cells. The results have shown that this Crbn-I391V KI mice model can be used to study the in vivo toxicity and efficacy of CRBN target drugs. (In collaboration with partners)
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
